Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219334 | 1.00 | LMNA (0.54) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL18661043 | 0.91 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216877 | 0.90 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216878 | 0.90 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL219535 | 0.89 | HSD17B1 (0.57) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL219536 | 0.89 | HSD17B1 (0.57) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL14087587 | 0.89 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738608 | 0.89 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL217503 | 0.88 | USP2 (0.52) | HSD17B1MAPTHRH3KDM4EALDH1A1 | |
| SCHEMBL217502 | 0.88 | USP2 (0.52) | HSD17B1MAPTHRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | LMNA 2693/4885HSD17B1 2/4885MAPT 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.